FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT05755048 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
BIOLOGICAL: Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.